CGEn Welcomes Two New Members to its Board of Directors
CGEn is pleased to welcome Drs. Dominique Bérubé and David Malkin to our Board of Directors. Their leadership, expertise, and commitment to advancing genomics-enabled research will strengthen CGEn’s vision to serve as Canada’s engine for genomics-enabled research and discovery, supporting a healthier and more sustainable future for all Canadians
Dr. Dominique Bérubé is the Vice-President, Research and Innovation, and Professor in the Faculty of Engineering at McGill University. With more than 22 years of experience across the academic, research, and innovation ecosystem, she brings deep expertise in research funding, strategic program development, major infrastructure initiatives, and Equity, Diversity and Inclusion leadership. A member of the Ordre des ingénieurs du Québec, Professor Bérubé holds a PhD in environmental sciences from UQAM and degrees in metallurgical and materials engineering from Polytechnique Montréal. Her previous leadership roles include serving as Vice-President of Research and Graduate Studies at Concordia University, Vice-President of Research at SSHRC, and Associate Vice-President of Research at Université de Montréal.
“I’m pleased to join the CGEn Board at a pivotal moment for precision health research in Canada. The future of medicine will rely on the responsible, large-scale use of genomic and health data to improve lives across diverse populations and health challenges. CGEn is at the forefront of this transformation, and I’m excited to contribute to its efforts to build national momentum in genomics-enabled research and innovation.” – Professor Dominique Bérubé
Dr. David Malkin is a clinician-scientist recognized internationally for his contributions to pediatric oncology and cancer genetics. A Professor of Paediatrics and Medical Biophysics at the University of Toronto, Dr. Malkin is a Staff Oncologist, Director of the Cancer Genetics Program, and Senior Scientist in the Genetics & Genome Biology Program at The Hospital for Sick Children, where he also co-leads the Precision Child Health initiative. His research focuses on the molecular basis of cancer susceptibility, particularly TP53 and Li-Fraumeni syndrome, and on applying genomics to early tumour detection and cancer interception. He has co-directed major national precision oncology programs, including KiCS and PROFYLE, advancing the integration of next-generation sequencing into clinical trials for children and young adults with hard-to-treat cancers.
“I am excited to join the Board of Directors and work with the extraordinary scientists and leaders of the CGEn network. In addition to bringing my perspective as a practicing pediatric oncologist with a keen interest in bringing real-time innovative technologies in genome medicine to the bedside, I also look forward to learning more about the breadth of projects across the Canadian genome research landscape.” – Dr. David Malkin
CGEn looks forward to the insight and strategic leadership Drs. Bérubé and Malkin will bring as the organization continues to build capacity, embark on ambitious projects, and strengthen Canada’s genomics research ecosystem.